Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671564 | 0.91 | — | — | |
| SCHEMBL15980945 | 0.85 | CCR5 (0.39) | L3MBTL1 | |
| SCHEMBL15980949 | 0.84 | KMT2A (0.42) | L3MBTL1 | |
| SCHEMBL15980980 | 0.81 | STAT6 (0.40) | — | |
| SCHEMBL15980946 | 0.79 | SLC6A2 (0.44) | — | |
| SCHEMBL15980947 | 0.79 | SLC6A2 (0.44) | — | |
| SCHEMBL15980948 | 0.79 | SLC6A2 (0.40) | — | |
| SCHEMBL15980950 | 0.78 | CHRM3 (0.42) | — | |
| SCHEMBL14660563 | 0.77 | — | — | |
| SCHEMBL18560534 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189840-A1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9079928-B2 | Methylphenidate-oxoacid conjugates, processes of making and using the same | KEMPHARM, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMT, PNMT, SLC6A3 | SERPINE1 4372/4885L3MBTL1 445/4885 |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | SERPINE1 4168/4885L3MBTL1 432/4885 |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | SERPINE1 4168/4885L3MBTL1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.